Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Analysts' Corner
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, October 29, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Elan Corporation, plc (NYSE: ELN), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), ICON Public Limited Company (NASDAQ: ICLR), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), and Healthways, Inc. (NASDAQ: HWAY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Elan Corporation, plc Research Report
On October 24, 2013, Elan Corporation, plc (Elan) released its Q3 2013 results. Elan registered revenues from continuing operations of $48.6 million in Q3 2013, primarily attributable to $48.1 million royalty of 12% of global net sales of Tysabri for Q3 2013. The Company posted net loss from continuing operations of $13.8 million in Q3 2013, compared to a net loss from continuing operations of $299.3 million in Q3 2012. Basic and diluted loss per share from continuing operations was $0.03 in Q3 2013, compared to $0.51 in Q3 2012. The Full Research Report on Elan Corporation, plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/e996_ELN]
NPS Pharmaceuticals, Inc. Research Report
On October 24, 2013, NPS Pharmaceuticals, Inc. (NPS) announced the submission of a Biologic License Application (BLA) to the US Food and Drug Administration (FDA) for Natpara (recombinant human parathyroid hormone 1-84, rhPTH (1-84)). According to NPS, Natpara is a bioengineered replacement for endogenous parathyroid hormone (PTH) that NPS has developed for the treatment of hypoparathyroidism, a rare endocrine disorder in which the body produces insufficient levels of parathyroid hormone, a principal regulatory of the body's mineral homeostasis. Francois Nader, MD, President and CEO of NPS, stated, "Submitting our BLA for Natpara is a significant step forward for NPS in our effort to bring the first replacement therapy to patients with hypoparathyroidism." Nader continued, "Hypoparathyroidism patients face a significant burden of disease given the multitude of physical, cognitive, and emotional symptoms associated with this disorder." The Full Research Report on NPS Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/441a_NPSP]
ICON plc Research Report
On October 24, 2013, ICON plc (ICON) released its Q3 2013 results. ICON registered net revenue of $339.8 million, up $19.0% YoY in Q3 2013. The Company posted net income of $27.8 million, up 56.8% YoY in Q3 2013. ICON reported diluted EPS of $0.45, up 55.2% YoY in Q3 2013. Ciaran Murray, CEO of ICON, said, "For the quarter we are reporting revenue growth of 19% year on year and operating margins of 9.8%. We booked $415 million of net new business wins or a book to bill of 1.2, leaving us with a closing backlog of $2.97 billion. Consequently, we are raising our revenue guidance to the range of $1.325 -$1.330 billion and our earnings per share guidance to the range of $1.67-$1.70 for the financial year 2013." The Full Research Report on ICON plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/fbb0_ICLR]
Keryx Biopharmaceuticals Inc. Research Report
On October 17, 2013, Keryx Biopharmaceuticals Inc. (Keryx) announced that abstracts highlighting Zerenex (ferric citrate coordination complex), the Company's drug candidate for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with chronic kidney disease (CKD) on dialysis, have been selected for oral and poster presentations during the American Society of Nephrology (ASN) Kidney Week 2013 annual meeting. Keryx reported that the event will be held in Atlanta, Georgia from November 5 to November 10, 2013. The Full Research Report on Keryx Biopharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/27d2_KERX]
Healthways, Inc. Research Report
On October 24, 2013, Healthways, Inc. (Healthways) released its Q3 2013 results. Healthways registered revenues of $166.6 million in Q3 2013, which were flat as compared to Q3 2012. The Company reported net income of $1.8 million in Q3 2013, compared net income of $5.0 million in Q3 2012. Healthways' diluted EPS was $0.05 in Q3 2013, compared to diluted EPS of $0.15 in Q3 2012. Ben R. Leedle, Jr., President and CEO at Healthways, commented, "Healthways' financial results for the third quarter of 2013 were below our expectations, and we are lowering our financial guidance for 2013 for two primary reasons. The majority of the guidance change results from a much lower number of risk lives available in 2013 for our total population management services to health systems than was forecast in our previous guidance. A smaller but still important impact came from the normal fluctuations in the memberships of our commercial health plan customers, where we experienced a net reduction in lives compared with our expectations." The Full Research Report on Healthways, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/76fd_HWAY]
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
©2012 PR Newswire. All Rights Reserved.
Can't find what you're looking for?